Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › CA › Irvine › NPI 1023786233
Lab

Shoreline Diagnostics LLC

Shoreline Diagnostics LLC was paid $9.64M by Medicaid between Oct 2021 and Nov 2024, across 8 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 65% of everything it billed.

33Billing provider infoSHORELINE DIAGNOSTICS LLC
IRVINE, CA 92618
33aNPI1023786233assigned 09/01/2021
28Total paid$9.64M
24GClaims280,169
24DCodes billed8
24AFirst – last monthOct 2021 – Nov 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#76 of 561
Median peer was paid$222K
This provider vs. median43×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$500K$1.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20211,569$49K
2022146,300$4.97M
2023114,713$3.86M
2024incomplete17,587$761K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 65% 108,281 32,929 $6.25M
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 16% 91,290 28,961 $1.58M
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 14% 34,029 10,614 $1.33M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 4.0% 43,165 13,907 $387K
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) <1% 3,147 1,666 $81K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 181 144 $12K
G2024 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source <1% 58 58 $1K
87631 <1% 18 18 $54.96

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBISCHOFF, DOUGLAS (CEO)